Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience

Therapeutic Advances in Respiratory Disease

Volumn 12, Issue , 2018, Pages

  Rivera Ortega, Pilar ^a   Hayton, Conal ^a   Blaikley, John ^a   Leonard, Colm ^a   Chaudhuri, Nazia ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

antifibrotic; idiopathic pulmonary fibrosis; interstitial lung disease; nintedanib

Indexed keywords

NINTEDANIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; FIBROSING ALVEOLITIS; HUMAN; LUNG TRANSPLANTATION; MORTALITY RATE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; ANIMAL; CHEMICALLY INDUCED; DIARRHEA; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; DIARRHEA; DISEASE PROGRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PROTEIN KINASE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 85054630709     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753466618800618     Document Type: Review

References (48)

1. Hutchinson J, Fogarty A, Hubbard R. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015; 46: 795–806
2. Bjoraker JA, Ryu JH, Edwin MK. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199–203
3. Ley B, Collard HR, King TE, Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431–440
4. Raghu G, Collard HR, Egan JJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824
5. Demedts M, Behr J, Buhl R. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229–2242
6. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968–1977
7. Hilberg F, Roth GJ, Krssak M. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774–4782
8. Wollin L, Maillet I, Quesniaux V. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014; 349: 209–220
9. Wollin L, Wex E, Pautsch A. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1434–1445
10. Richeldi L, Costabel U, Selman M. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079–1087
11. Richeldi L, du Bois RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082
12. Richeldi L, Cottin V, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med 2016; 113: 74–79
13. Collard HR, Richeldi L, Kim DS. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J 2017; 49
14. Richeldi L, Kreuter M, Selman M. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax 2018; 73: 581–583
15. Crestani B, Quaresma M, Kaye M. Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON. Eur Respir J 2016; 48
16. Huggins J, Meyer K, Stansen W. No effect of dose adjustments on long-term reduction in FVC decline with nintedanib in patients with idiopathic pulmonary fibrosis (IPF). Chest 2017; 152
17. Crestani B, Kolb M, Wallaert B. M33 Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (ipf) irrespective of dose: subgroup analysis of inpulsis-on. Thorax 2017; 72: A255–A255
18. Costabel U, Inoue Y, Richeldi L. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193: 178–185
19. Taniguchi H, Xu Z, Azuma A. Subgroup analysis of Asian patients in the INPULSIS((R)) trials of nintedanib in idiopathic pulmonary fibrosis. Respirology 2016; 21: 1425–1430
20. Kolb M., Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017; 72: 340–346
21. Wuyts WA, Kolb M, Stowasser S. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of
22. Raghu G, Wells AU, Nicholson AG. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med 2017; 195: 78–85
23. Kreuter M, Costabel U, Richeldi L. Statin therapy and outcomes in trials of nintedanib in idiopathic pulmonary fibrosis. Respiration 2018; 95: 317–326
24. Corte T, Bonella F, Crestani B. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015; 16: 116
25. Schmid U, Doege C, Dallinger C. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2018; 48: 136–143
26. Schmid U, Weber B, Dallinger C. Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis. Eur Respir J 2016; 48
27. Marzin K, Kretschmar G, Luedtke D. Pharmacokinetics of nintedanib in subjects with hepatic impairment. J Clin Pharmacol. Epub ahead of print 6 November 2017. DOI: 10.1002/jcph.1025
28. Luedtke D, Marzin K, Jungnik A. Effects of ketoconazole and rifampicin on the pharmacokinetics of nintedanib in healthy subjects. Eur J Drug Metab Pharmacokinet. Epub ahead of print 2 March 2018. DOI: 10.1007/s13318-018-0467-9
29. Bonella F, Kreuter M, Hagmeyer L. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration 2016; 92: 98–106
30. Valenzuela C, Molina M, Diaz Chantar F. Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): about 20 cases. Eur Respir J 2015; 46
31. Tzouvelekis A, Karampitsakos T, Kontou M. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study in Greece. Pulm Pharmacol Ther 2018; 49: 61–66
32. Toellner H, Hughes G, Beswick W. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clin Transl Med 2017; 6: 41
33. Harari S, Caminati A, Poletti V. A real-life multicenter national study on nintedanib in severe idiopathic pulmonary fibrosis. Respiration 2018; 95: 433–440
34. Brunnemer E, Walscher J, Tenenbaum S. Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis. Respiration 2018; 95: 301–309
35. Galli JA, Pandya A, Vega-Olivo M. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology 2017; 22: 1171–1178
36. Weir NA, Poreddy M, Scully A. Gender and BMI predict antifibrotic tolerance in IPF. B103 ILD: Management A4259–A4259
37. Kistler KD, Nalysnyk L, Rotella P. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 2014; 14: 139
38. Delanote I, Wuyts WA, Yserbyt J. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med 2016; 16: 156
39. Balestro E, Solidoro P, Parigi P. Safety of nintedanib before lung transplant: an Italian case series. Respirol Case Rep 2018; 6: e00312
40. Leuschner G, Stocker F, Veit T. Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant. Epub ahead of print 5 July 2017. DOI: 10.1016/j.healun.2017.07.002
41. Lambers C, Boehm PM, Lee S. Effect of antifibrotics on short-term outcome after bilateral lung transplantation a multi-centre analysis. Eur Respir J 2018; 51. DOI: 10.1183/13993003.00503–2018
42. Ogura T, Taniguchi H, Azuma A. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1382–1392
43. Vancheri C, Kreuter M, Richeldi L. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial. Am J Respir Crit Care Med 2018; 197: 356–363
44. Redente EF, Aguilar MA, Black BP. Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2018; 314: L998–L1009
45. Huang J, Maier C, Zhang Y. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis 2017; 76: 1941–1948
46. Distler O, Brown KK, Distler JHW. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). Clin Exp Rheumatol 2017; 35(Suppl. 106): 75–81
47. Flaherty KR, Brown KK, Wells AU. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017; 4: e000212
48. De Ruysscher D, Granton PV, Lieuwes NG. Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: a preclinical study with a high precision image-guided irradiator. Radiother Oncol 2017; 124: 482–487